EcoDrugPlus

C-Reactive Protein

Ensembl ID : ENSOKIG00005014801
Gene Symbol: LOC109865115
2 Cross references
350 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSOKIG00005008228
Gene Symbol: LOC109875509
2 Cross references
326 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOKIG00005047693
Gene Symbol: CFTR
1 Cross references
210 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSOKIG00005050262
Gene Symbol: LOC109892175
3 Cross references
192 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSOKIG00005035960
Gene Symbol: LOC109872486
3 Cross references
191 Possible Orthologues:

D(2)-Like Dopamine Receptor

Ensembl ID : ENSOKIG00005027310
Gene Symbol: LOC109909573
3 Cross references
203 Possible Orthologues:

D(4) Dopamine Receptor

Ensembl ID : ENSOKIG00005032941
Gene Symbol: LOC109897456
3 Cross references
131 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSOKIG00005019681
Gene Symbol: LOC109877259
3 Cross references
180 Possible Orthologues:

Dna (Cytosine-5)-Methyltransferase 1

Ensembl ID : ENSOKIG00005032606
Gene Symbol: LOC109893479
3 Cross references
204 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSOKIG00005002092
Gene Symbol: DNMT1
1 Cross references
204 Possible Orthologues:

Dna Topoisomerase 1

Ensembl ID : ENSOKIG00005014623
Gene Symbol: LOC109897698
3 Cross references
201 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSOKIG00005001118
Gene Symbol: LOC109890961
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).